Cargando…
Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes
GAD-alum given into lymph nodes to type 1 diabetes patients participating in an open-label pilot trial resulted in preservation of C-peptide similar to promising results from other trials. Here, we compared the immunomodulatory effect of giving GAD-alum directly into lymph nodes versus that induced...
Autores principales: | Tavira, Beatriz, Barcenilla, Hugo, Wahlberg, Jeannette, Achenbach, Peter, Ludvigsson, Johnny, Casas, Rosaura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994289/ https://www.ncbi.nlm.nih.gov/pubmed/30009185 http://dx.doi.org/10.1155/2018/9391845 |
Ejemplares similares
-
Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype
por: Puente-Marin, Sara, et al.
Publicado: (2023) -
Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients
por: Casas, Rosaura, et al.
Publicado: (2020) -
Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
por: Casas, Rosaura, et al.
Publicado: (2022) -
Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes
por: Barcenilla, Hugo, et al.
Publicado: (2022) -
Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD(65)-induced immune response
por: Tavira, Beatriz, et al.
Publicado: (2017)